Female reproductive health in pediatric, adolescent, and young adult cancer survivors

Abstract

An estimated 500,000 cancer survivors of reproductive age in the United States will live to experience the long‐term consequences of cancer treatment. Therefore, a focused aspect of cancer care has appropriately shifted to include quality of life in survivorship. Infertility is a late effect of therapy that affects 12% of female survivors of childhood cancer receiving any cancer treatment in large cohort studies and results in a 40% decreased likelihood of pregnancy in young adults of ages 18–39 years. Nonfertility gynecologic late effects such as hypoestrogenism, radiation‐induced uterine and vaginal injury, genital graft‐versus‐host disease after hematopoietic stem cell transplant, and sexual dysfunction also significantly affect quality of life in survivorship but are underdiagnosed and require consideration. Several articles in the special edition “Reproductive Health in Adolescent and Young Adult Cancer Survivorship” address infertility, genital graft‐versus‐host disease, and psychosexual functioning in survivorship. This review article focuses on other adverse gynecologic outcomes of cancer therapies including hypogonadism and hormone replacement therapy, radiation‐induced uterovaginal injury, vaccination and contraception, breast and cervical cancer screening, and pregnancy considerations in survivorship.

Consenso Anticoncepción Hormonal. Actualización 2023. CAPÍTULO 6.

“…Es particularmente importante proporcionar educación anticonceptiva a los sobrevivientes de cáncer pediátrico y juvenil. Solo el 33 % de las mujeres sobrevivientes de cáncer informaron el uso efectivo de anticonceptivos según lo descrito por la Organización Mundial de la Salud, incluida la esterilización, la anticoncepción reversible de acción prolongada u otros métodos hormonales (90).…”